A citation-based method for searching scientific literature

Alice T Shaw, Benjamin J Solomon, Rita Chiari, Gregory J Riely, Benjamin Besse, Ross A Soo, Steven Kao, Chia-Chi Lin, Todd M Bauer, Jill S Clancy, Holger Thurm, Jean-Francois Martini, Gerson Peltz, Antonello Abbattista, Sherry Li, Sai-Hong Ignatius Ou. Lancet Oncol 2019
Times Cited: 135



Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf, Takashi Seto, Byoung Chul Cho, Manish R Patel, Chao-Hua Chiu, Thomas John, Koichi Goto, Christos S Karapetis, Hendrick-Tobias Arkenau, Sang-We Kim, Yuichiro Ohe, Yu-Chung Li, Young K Chae, Christine H Chung, Gregory A Otterson, Haruyasu Murakami, Chia-Chi Lin, Daniel S W Tan, Hans Prenen, Todd Riehl, Edna Chow-Maneval, Brian Simmons, Na Cui, Ann Johnson, Susan Eng, Timothy R Wilson, Robert C Doebele. Lancet Oncol 2020
Times Cited: 163




List of shared articles



Times cited

Post-chemotherapy and targeted therapy imaging of the chest in lung cancer.
B W Carter, M Altan, G S Shroff, M T Truong, I Vlahos. Clin Radiol 2022
1

Rare driver alterations in nonsmall cell lung cancer: novel targeted drugs.
Diego Kauffmann-Guerrero, Amanda Tufman. Curr Opin Oncol 2022
1

Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
Clare Keddy, Pushkar Shinde, Kristen Jones, Stefanie Kaech, Romel Somwar, Ujwal Shinde, Monika A Davare. Mol Cancer Ther 2022
1


Managing Central Nervous System Spread of Lung Cancer: The State of the Art.
David Chun Cheong Tsui, D Ross Camidge, Chad G Rusthoven. J Clin Oncol 2022
2

Complications following novel therapies for non-small cell lung cancer.
Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, Simon Ekman. J Intern Med 2022
0

ROS-1 Fusions in Non-Small-Cell Lung Cancer: Evidence to Date.
Sébastien Gendarme, Olivier Bylicki, Christos Chouaid, Florian Guisier. Curr Oncol 2022
0

Lorlatinib for advanced ROS1+ non-small-cell lung cancer: results of the IFCT-1803 LORLATU study.
N Girard, S Galland-Girodet, V Avrillon, B Besse, M Duruisseaux, J Cadranel, J Otto, A Prevost, B Roch, J Bennouna,[...]. ESMO Open 2022
1

Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trial.
A S Mansfield, Z Wei, R Mehra, A T Shaw, C H Lieu, P M Forde, A E Drilon, E P Mitchell, J J Wright, N Takebe,[...]. NPJ Precis Oncol 2022
2

SEOM-GEINO clinical guideline of systemic therapy and management of brain central nervous system metastases (2021).
María Martínez-García, Sonia Servitja Tormo, Noelia Vilariño Quintela, Ana Arance Fernández, Alfonso Berrocal Jaime, Blanca Cantos Sánchez de Ibargüen, Sonia Del Barco Berrón, Rosario García Campelo, Regina Gironés Sarrió, Juan Manuel Sepúlveda-Sánchez. Clin Transl Oncol 2022
2

Targeted therapy in lung cancer: Are we closing the gap in years of life lost?
David J Benjamin, Alyson Haslam, Jenny Gill, Vinay Prasad. Cancer Med 2022
0

Novel targeted therapies for advanced non-small lung cancer.
Omar Abughanimeh, Anahat Kaur, Badi El Osta, Apar Kishor Ganti. Semin Oncol 2022
0

Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer.
Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman. Int J Mol Sci 2022
0

Biomarker guided treatment in oncogene-driven advanced non-small cell lung cancer in older adults: A Young International Society of Geriatric Oncology Report.
Konstantinos Christofyllakis, Ana Raquel Monteiro, Onur Cetin, Igor Age Kos, Alastair Greystoke, Andrea Luciani. J Geriatr Oncol 2022
0

Strengths and pitfalls of brigatinib in non-small cell lung cancer patients' management.
Fabrizio Tabbò, Marco DE Filippis, Francesca Jacobs, Silvia Novello. Minerva Med 2022
0

ROS1-positive non-small cell lung cancer (NSCLC): biology, diagnostics, therapeutics and resistance.
Zhi-Qiong Yu, Meng Wang, Wen Zhou, Meng-Xia Mao, Yuan-Yuan Chen, Na Li, Xiao-Chun Peng, Jun Cai, Zhi-Qiang Cai. J Drug Target 2022
0

Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion-Positive NSCLC.
Alexander Drilon, Chao-Hua Chiu, Yun Fan, Byoung Chul Cho, Shun Lu, Myung-Ju Ahn, Matthew G Krebs, Stephen V Liu, Thomas John, Gregory A Otterson,[...]. JTO Clin Res Rep 2022
0

Brain Metastases Management in Oncogene-Addicted Non-Small Cell Lung Cancer in the Targeted Therapies Era.
Elisa De Carlo, Elisa Bertoli, Alessandro Del Conte, Brigida Stanzione, Eleonora Berto, Alberto Revelant, Michele Spina, Alessandra Bearz. Int J Mol Sci 2022
0

Targeting molecular alterations in non-small-cell lung cancer: what's next?
Rafael López-Castro, Tania García-Peña, Xabier Mielgo-Rubio, Mariona Riudavets, Cristina Teixidó, Noelia Vilariño, Felipe Couñago, Laura Mezquita. Per Med 2022
0

A Phase 2 Study of Lorlatinib in Patients With ROS1-Rearranged Lung Cancer With Brain-Only Progression on Crizotinib.
Jaime L Schneider, Alona Muzikansky, Jessica J Lin, Elizabeth A Krueger, Inga T Lennes, Joseph O Jacobson, Michael Cheng, Rebecca S Heist, Zofia Piotrowska, Justin F Gainor,[...]. JTO Clin Res Rep 2022
0

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
43


Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
5

Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update.
Nasser H Hanna, Andrew G Robinson, Sarah Temin, Sherman Baker, Julie R Brahmer, Peter M Ellis, Laurie E Gaspar, Rami Y Haddad, Paul J Hesketh, Dharamvir Jain,[...]. J Clin Oncol 2021
80

Systemic Therapy for Mutation-Driven NSCLC.
Lova Sun, Melina E Marmarelis, Corey J Langer. Semin Radiat Oncol 2021
1

Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.
Rafal Dziadziuszko, Matthew G Krebs, Filippo De Braud, Salvatore Siena, Alexander Drilon, Robert C Doebele, Manish R Patel, Byoung Chul Cho, Stephen V Liu, Myung-Ju Ahn,[...]. J Clin Oncol 2021
24


Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
15

Fusion proteins in lung cancer: addressing diagnostic problems for deciding therapy.
Federica Zito Marino, Greta Alì, Francesco Facchinetti, Luisella Righi, Gabriella Fontanini, Giulio Rossi, Renato Franco. Expert Rev Anticancer Ther 2021
4

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
3

Current treatment and future challenges in ROS1- and ALK-rearranged advanced non-small cell lung cancer.
Jordi Remon, Daniele Pignataro, Silvia Novello, Francesco Passiglia. Cancer Treat Rev 2021
9

Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
Francesco Facchinetti, Antonin Levy, Samy Ammari, Charles Naltet, Pernelle Lavaud, Mihaela Aldea, Damien Vasseur, David Planchard, Benjamin Besse. Cancer Manag Res 2021
2

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
12

Efficacy of lorlatinib in lung carcinomas carrying distinct ALK translocation variants: The results of a single-center study.
Sergey V Orlov, Aglaya G Iyevleva, Elena A Filippova, Alexandra M Lozhkina, Svetlana V Odintsova, Tatiana N Sokolova, Natalia V Mitiushkina, Vladislav I Tiurin, Elena V Preobrazhenskaya, Alexandr A Romanko,[...]. Transl Oncol 2021
2

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
2

Safety but Limited Efficacy of Ensartinib in ROS1-Positive NSCLC: A Single-Arm, Multicenter Phase 2 Study.
Xinghao Ai, Qiming Wang, Ying Cheng, Xiaoqing Liu, Lejie Cao, Jianhua Chen, Xiaorong Dong, Jianying Zhou, Yun Fan, Cheng Huang,[...]. J Thorac Oncol 2021
2

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
112


First-Line Treatment of Metastatic Non-Small Cell Lung Cancer in the Elderly.
Tania Losanno, Cesare Gridelli. Curr Oncol Rep 2021
0

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
13

Toward personalized treatment approaches for non-small-cell lung cancer.
Meina Wang, Roy S Herbst, Chris Boshoff. Nat Med 2021
44

How clinically useful is comprehensive genomic profiling for patients with non-small cell lung cancer? A systematic review.
Gabriel Fernando Torres, Carlos Eduardo Bonilla, Giancarlo Buitrago, Oscar Arrieta, Umberto Malapelle, Christian Rolfo, Andrés F Cardona. Crit Rev Oncol Hematol 2021
2

Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
Noura J Choudhury, Jaime L Schneider, Tejas Patil, Viola W Zhu, Debra A Goldman, Soo-Ryum Yang, Christina J Falcon, Andrew Do, Yunan Nie, Andrew J Plodkowski,[...]. JTO Clin Res Rep 2021
3


Recent advances in lung cancer genomics: Application in targeted therapy.
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. Adv Genet 2021
1

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
3


Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
10

An annual review of the remarkable advances in lung cancer clinical research in 2019.
Bo Cheng, Shan Xiong, Caichen Li, Hengrui Liang, Yi Zhao, Jianfu Li, Jiang Shi, Limin Ou, Zisheng Chen, Peng Liang,[...]. J Thorac Dis 2020
12

Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives.
Miriam Grazia Ferrara, Vincenzo Di Noia, Ettore D'Argento, Emanuele Vita, Paola Damiano, Antonella Cannella, Marta Ribelli, Sara Pilotto, Michele Milella, Giampaolo Tortora,[...]. Cancers (Basel) 2020
30